Subcutaneous Administration of Amifostine During Fractionated Radiotherapy: A Randomized Phase II Study
Top Cited Papers
- 11 June 2000
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 18 (11) , 2226-2233
- https://doi.org/10.1200/jco.2000.18.11.2226
Abstract
PURPOSE: Amifostine (WR-2721) is an impotant cytoprotective agent. Although intravenous administration is the standard route, pharmacokinetic studies have shown acceptable plasma levels of the acti...Keywords
This publication has 21 references indexed in Scilit:
- Fractionated Carboplatin RadiosensitizationAmerican Journal of Clinical Oncology, 1998
- Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesisNature, 1998
- Thiol WR-1065 and disulphide WR-33278, two metabolites of the drug Ethyol (WR-2721), protect DNA against fast neutroninduced strand breakageInternational Journal of Radiation Biology, 1997
- Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of actionCarcinogenesis: Integrative Cancer Research, 1995
- Competition for Polyamine Uptake into Rat Lung Slices by WR2721 and AnaloguesInternational Journal of Radiation Biology, 1989
- Pharmacokinetics of WR-2721Pharmacology & Therapeutics, 1988
- Human pharmacokinetics of WR-2721International Journal of Radiation Oncology*Biology*Physics, 1986
- Alterations in oxygen transport following WR-2721International Journal of Radiation Oncology*Biology*Physics, 1984
- Interaction of Cultured Mammalian Cells with WR-2721 and Its Thiol, WR-1065: Implications for Mechanisms of RadioprotectionInternational Journal of Radiation Biology, 1983
- Mechanism of Action of Aminothiol RadioprotectorsNature, 1967